C
Description
Multi-disciplinary UK contract research organization (CRO) combining translational biology with end-to-end chemistry expertise for drug discovery and development. Operates facilities in Chapel-en-le-Frith, Edinburgh, Dundee and Sandwich. Has accelerated 30 candidates to preclinical, 21 to clinic, and 4 to market. Acquired by Limerston Capital in 2023.